– March 1, 2003
March 1, 2003
View Archives Issues
-
Cancer Treatment in the Oldest-Old: Evidence for an Age Bias Against the Use of Tamoxifen
Doctors tend to prescribe less tamoxifen to the oldest-old and also to those with significant comorbidities (in both age groups) or those unmarried and without living children. With increasing life expectancy currently being observed in these age groups, this study raises the possibility that oncologists may be missing the opportunity to help the oldest breast cancer patients achieve therapeutic benefit from tamoxifen. -
Omission of Chemoradiation is Associated with Poor Survival in Medicare Patients with Resected Pancreas Cancer
Outcomes following resection of pancreas cancer have improved recently, more than can be accounted for by a drop in procedure-related mortality. This study from the Harvard School of Public Health performed a retrospective analysis of claims-based Medicare data and correlated it with SEER data to identify prognostic factors that may be contributing to this phenomenon. -
Lung Cancer in Asian Immigrants: More-Advanced Disease, Less-Favorable Outcomes
In a 5-year retrospective analysis of lung cancer in Asian immigrants living in Boston and seen at the New England Medical Center, more-advanced disease and shorter survival was observed when compared to non-Asian, and age- and gender-matched controls. -
CHOP and Non-Hodgkin’s Lymphoma
CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) is still considered the gold standard in first-line therapy for aggressive non-Hodgkins lymphoma. Despite its place in clinical practice for 3 decades, there are issues that still are being evaluated. -
Anti-HER2 Antibody, Trastuzumab in Patients with Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma with Overexpression of HER2
The clinical value of single-agent trastuzumab in recurrent ovarian cancer is limited by the low frequency of HER2 overexpression and low rate of objective response among patients with HER2 overexpression. -
Clinical Briefs in Primary Care Supplement